|
|
|
|
|
|
|
02.10.26 - 08:36
|
AZ & DS collaboration with Summit for Datroway (Cision)
|
|
|
02 October 2026
AstraZeneca and Daiichi Sankyo announce clinical collaboration
with Summit Therapeutics to evaluate Datroway in combination
with ivonescimab across multiple tumour types
Builds on recently announced clinical collaboration between AstraZeneca
and Summit to advance leading ADC combination strategy in cancer
AstraZeneca and Daiichi Sankyo have entered into a clinical collaboration agreement with Summit Therapeutics Inc. to evaluate Datroway (datopotamab deruxtecan) in combination with ivonescimab across multiple tumour types including lung and breast cancers. The...
|
|
|
28.09.26 - 12:24
|
Daiichi Sankyo, MSD withdraw cancer drug application (PBR)
|
|
|
The companies submitted the application seeking accelerated approval in the US. Their decision to withdraw follows discussions with the US Food and Drug Administration (FDA), which indicated that
The post Daiichi Sankyo, MSD withdraw cancer drug application appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
|
|
|
21.09.26 - 08:01
|
Enhertu recommended for approval in EU in early BC (Cision)
|
|
|
21 September 2026
Enhertu recommended for approval in the EU by CHMP as adjuvant treatment for patients with residual disease after neoadjuvant treatment for HER2-positive early breast cancer
Based on DESTINY-Breast05 Phase III trial which showed Enhertu reduced the risk of invasive disease recurrence or death by 53% vs. T-DM1
AstraZeneca and Daiichi Sankyo's Enhertu has the potential to become a new standard of care in this early breast cancer setting
AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU)...
|
|
|
17.09.26 - 13:18
|
Fortis moves Supreme Court against Delhi High Court order (Times of India)
|
|
|
Fortis Healthcare has appealed to the Supreme Court against a recent Delhi High Court order. The order mandated a forensic audit of Fortis's dealings with IHH Healthcare and RHT Health Trust. This legal battle stems from Daiichi Sankyo's efforts to enforce an arbitral award against former promoters. Fortis argues the high court order unfairly impacts its public shareholders and IHH....
|
|
|
|
|
|
|
|
|
|
|
01.09.26 - 08:30
|
Enhertu approved in EU for 1L HER2-positive mBC (Cision)
|
|
|
01 September 2026
Enhertuplus pertuzumab approved in the EU as first new regimen in more than a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer
Based on DESTINY-Breast09 Phase III trial which showed AstraZeneca and Daiichi Sankyo's Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP with median progression-free survival exceeding three years
AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) in combination with pertuzumab has been approved in the European Union (EU) for the 1st-line...
|
|
|
31.08.26 - 07:48
|
AAX Biotech Enters Next Phase of Collaboration with Daiichi Sankyo Following Initial Evaluation of Opti-mAb® Technology (Cision)
|
|
|
Swedish biotech company AAX Biotech AB today announced that its research and development collaboration with Daiichi Sankyo (TSE: 4568) has progressed into a new phase. Following an initial evaluation of AAX Biotech's proprietary Opti-mAb® technology, the companies have agreed to advance their collaboration into an antibody program, marking the next step in exploring the technology's potential in next-generation antibody therapeutics.
[AAX-Biotech-Daiichi-Sankyo-advance-collaboration-Opti-mAb.png]
AAX Biotech pioneers innovative technologies that advance the development of next-generation...
|
|
|
24.08.26 - 10:03
|
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization (Business Wire)
|
|
|
MUNICH--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe.
The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region.
For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Dai...
|
|
|
24.08.26 - 09:06
|
Daiichi Sankyo Appoints Ken Keller as Chief Commercialization Officer to Lead New Commercialization Unit to Accelerate Growth of Innovative Portfolio (Business Wire)
|
|
|
TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) has appointed Ken Keller to the newly created role of Chief Commercialization Officer, responsible for accelerating further growth of the company's oncology and specialty medicine business through a new globally integrated Commercialization Unit, effective April 1, 2027.
As part of the operational excellence pillar outlined in the new Five-Year Business Plan of Daiichi Sankyo in May 2026, commercialization activities will be centralized and reorganized to drive greater speed and consistency, while optimizing resource management and investment decisions as part of the company's ambition to become a global top five oncology company by 2035.
In addition to the new Chief Commercialization Officer role, Ken will remain a member of the Board of Directors of Daiichi Sankyo Company, Limited, as well as the Chairman of the Board, President and CEO of Daiichi Sankyo, Inc., the company's U.S. subsidiary. Ken joined Daiichi Sankyo in 2014 and has served as the Hea...
|
|
|
|
|
17.08.26 - 08:30
|
Enhertu improved PFS in 1L HER2m lung cancer (Cision)
|
|
|
17 August 2026
Enhertu demonstrated statistically significant and clinically meaningful improvement in
progression-free survival as 1st-line treatment of patients with HER2-mutant advanced
non-small cell lung cancer in
DESTINY-Lung04 Phase III trial
AstraZeneca and Daiichi Sankyo's Enhertu is the first and only
HER2-directed medicine to improve progression-free survival
over global standard of care in a Phase III trial in this setting
Positive high-level results from the DESTINY-Lung04 Phase III trial showed Enhertu (trastuzumab deruxtecan) demonstrated a statistically...
|
|
|
10.08.26 - 12:36
|
Innovent and Daiichi Sankyo sign deal for Vanflyta in China (PBR)
|
|
|
Under the contract, Daiichi Sankyo will continue to handle development, manufacturing, and supply of the therapy while Innovent Biologics will lead market promotion and commercialisation activities in China.
The post Innovent and Daiichi Sankyo sign deal for Vanflyta in China appeared first on Pharmaceutical Business review....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
